Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

319
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
319
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

235
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
235
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

670
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
670

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes.

The Journal of clinical and aesthetic dermatology·2025
Same author

Advances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2024
Same author

Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report

Journal of drugs in dermatology : JDD·2024
Same author

Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.

Journal of drugs in dermatology : JDD·2023
Same author

New Technologies in Diagnosis and Prognosis of Melanocytic Lesions.

The Journal of clinical and aesthetic dermatology·2023
Same author

High-Quality Lipoaspirate Following 1470-nm Radial Emitting Laser-Assisted Liposuction.

Annals of plastic surgery·2022

Related Experiment Video

Updated: Mar 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Biosimilars in psoriasis: the future or not?

Roselyn Kellen1, Gary Goldenberg2

  • 1Weill Cornell Medical College, New York, New York, USA.

Cutis
|March 21, 2017
PubMed
Summary
This summary is machine-generated.

Biosimilars, highly similar to reference biologics, are nearing patent expiration. Dermatologists must prepare for their integration into patient care and the healthcare system.

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

973
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

973
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Area of Science:

  • Dermatology
  • Pharmacology
  • Health Policy

Background:

  • Biologic agent patents are expiring, leading to the introduction of biosimilars.
  • Biosimilars are highly similar, but not identical, to reference products due to complex manufacturing.
  • The US Food and Drug Administration (FDA) has approved biosimilars for conditions like plaque psoriasis and psoriatic arthritis.

Purpose of the Study:

  • To discuss the implications of biosimilar availability in dermatology.
  • To address regulatory and clinical considerations for biosimilar adoption.
  • To examine the impact of biosimilars on patient care within the healthcare system.

Main Methods:

  • Review of FDA guidelines on biosimilar approval.
  • Analysis of the differences between biosimilars and small-molecule generics.
  • Discussion of healthcare system integration challenges.

Main Results:

  • Biosimilars have been approved by the FDA for specific dermatological indications.
  • Technical challenges exist regarding identicality and automatic substitution.
  • Biosimilars necessitate careful integration into existing healthcare structures.

Conclusions:

  • Dermatologists need to prepare for the influx of biosimilars.
  • Key questions remain regarding indication approval and pharmacy substitution.
  • Successful integration of biosimilars requires consideration of the broader healthcare ecosystem.